Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
| Autor: | Shan Feng, Nina Weis, Lotte S. Mikkelsen, Carlota Fernandez-Antunez, Anna-Louise Sørensen, Anders Fomsgaard, Anni Assing Winckelmann, Alexander P. Underwood, Jens Bukh, Santseharay Ramirez, Signe Bollerup, Ulrik Fahnøe, Christina Sølund, Signe Lysemose Villadsen, Ria Lassaunière |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
IgA binding
Adult Male Medicine (General) Coronavirus disease 2019 (COVID-19) IgG Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Enzyme-Linked Immunosorbent Assay Antibodies Viral Severity of Illness Index General Biochemistry Genetics and Molecular Biology Neutralization Persistence (computer science) neutralisation R5-920 Medicine Humans neutralising antibodies Independent research biology business.industry SARS-CoV-2 COVID-19 General Medicine Middle Aged Antibodies Neutralizing Immunoglobulin A IgG binding Immunoglobulin G Immunology biology.protein Female Antibody business IgA Research Paper |
| Zdroj: | EBioMedicine Underwood, A P, Sølund, C, Fernandez-Antunez, C, Villadsen, S L, Winckelmann, A A, Bollerup, S, Mikkelsen, L S, Sørensen, A L, Feng, S, Fahnøe, U, Lassauniere, R, Fomsgaard, A, Ramirez, S, Weis, N & Bukh, J 2021, ' Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19 ', EBioMedicine, vol. 71, 103519 . https://doi.org/10.1016/j.ebiom.2021.103519 EBioMedicine, Vol 71, Iss, Pp 103519-(2021) |
| ISSN: | 2352-3964 |
| DOI: | 10.1016/j.ebiom.2021.103519 |
| Popis: | Background: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals with mild COVID-19. Methods: Plasma neutralisation titres in convalescent COVID-19 individuals were determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay. Total SARS-CoV-2 spike-specific IgG and IgA binding was measured using a lectin capture ELISA and compared between timepoints and correlated to neutralising titres. Findings: All 48 convalescent COVID-19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres (ID50) at baseline and 6 months post-symptom onset with mean ID50 of 1/943 and 1/411, respectively. SARS-CoV-2 neutralisation titres peaked within 1-2 months post-symptom onset. However, 50% of individuals showed comparable ID50 at baseline and 6 months post-symptom onset. Both SARS-CoV-2 spike-specific IgG and IgA levels correlated well with neutralising titres. IgG binding was found to be sustained up to 6 months post-symptom onset, whereas IgA levels declined. Interpretation: This study demonstrates durability of SARS-CoV-2 spike-specific IgG and neutralisation responses following recovery from mild COVID-19. Thus, all subjects included in this study might potentially have protective levels of neutralising antibodies 6 months post-symptom onset. This study also demonstrates a relationship between spike-specific IgA and neutralisation decline, with implications for long-term protection against SARS-CoV-2 infection. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark and Danish Agency for Science and Higher Education. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|